Skip to content

Aquestive Therapeutics, Inc. AQST Warrants And Rights Outstanding

Warrants And Rights Outstanding at other companies

Lithium Americas logo
Lithium AmericasLAC
$144.89M
Plug Power logo
Plug PowerPLUG
$106.96M
Nuvation Bio logo
Nuvation BioNUVB
$2.87M+39.6%
Toast logo
ToastTOST
$11M-42.1%
American Resources Investment Trust Inc logo
American Resources Investment Trust IncINV
$27.82M+15.9%
Rumble, Inc. logo
Rumble, Inc.RUM
$8.61M-53.4%

Other financials

Income statement

See full
Revenue$14.4M+65.7%
Gross profit$11.0M+117%
Operating income-$4.2M+78.3%
Net income-$8.1M+64.9%
EPS (diluted)-$0.07+70.8%

Balance sheet

See full
Cash & equivalents$110.7M+61.3%
Total debt$64.4M+7.4%
Total equity-$34.1M+44.1%
Total assets$141.1M+38.0%

Cash flow

See full
Operating cash flow-$14.8M+36.7%
CapEx$52.0K-61.5%
Free cash flow-$14.9M+36.9%

Valuation

See full
Market cap$560.13M+73.5%
Enterprise value$513.76M+63.6%
P/S11.1×+5.2×

Profitability

See full
Gross margin63.5%-4.9pp
Operating margin-111.2%+96.3pp
Net margin-137.1%+80.7pp
FCF margin-88.2%-2.2pp

Returns & leverage

See full
Return on equity145.1%
Debt / equity-1.9×
Current ratio4.1×-0.8×

Where this comes from

Reported directly by Aquestive Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:WarrantsAndRightsOutstanding.

The official record: Aquestive Therapeutics, Inc.’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Aquestive Therapeutics, Inc.'s warrants and rights outstanding.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Aquestive Therapeutics, Inc.'s warrants and rights outstanding?
Aquestive Therapeutics, Inc. (AQST) reported warrants and rights outstanding of $916K in Q1 2026.
What does warrants and rights outstanding mean?
This represents the total value or number of equity-linked instruments that grant holders the right to purchase shares of the company at a specified price. These instruments are often issued as part of financing arrangements or incentive packages. Investors monitor this to assess the potential for future equity dilution and the impact on earnings per share.